1648 - OncoSil™ for locally advanced unresectable pancreatic cancer

Page last updated: 01 October 2020

Application Detail

Description of Medical Service

OncoSil™ is a device that imparts a pre-determined dose of beta radiation directly into cancerous pancreatic tissue. The beta particles emitted by OncoSil™ travel a short distance in tissue causing damage to cancer cell DNA, which renders them incapable of further cell division and proliferation. OncoSil in combination with Gemcitabine or FOLFIRINOX is considered to be a better treatment option for locally advanced unresectable pancreatic cancer.

There are three proposed medical services:

Nuclear Medicine
  • Professional attendance and handling for assessment and preparation of OncoSil™ microparticles for injection of by endoscopic ultrasound (endoscopy with ultrasound imaging).
  • Single-photon emission computed tomography Scan on Day 1 and Day 7 post OncoSil implantation
  • Injection of OncoSil™ by endoscopic ultrasound (endoscopy with ultrasound imaging)

Description of Medical Condition

Pancreatic cancer occurs when the malignant (cancerous) cells multiplies in the tissues of the gland. It often begins within the cells of pancreatic ducts, and subsequently spreading to the rest of the gland and surrounding regions. The cancer that begins in the ducts of pancreas affecting exocrine cells are called pancreatic adenocarcinoma or pancreatic exocrine cancer. Approximately 70% of the pancreatic cancer arises in the head of the pancreas. Rarely, the cancer initiates in the neuroendocrine cells of pancreas, called the islet cell carcinoma or pancreatic endocrine cancer.

Based on the spread and severity of the disease, pancreatic cancers can be grouped into resectable, borderline resectable, Locally advanced, and metastatic stages.

Reason for Application

New/Amendment to MBS item

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1417 KB)
Application Form (Word 360 KB)

Consultation Survey

Consultation Survey (PDF 557 KB)
Consultation Survey (Word 71 KB)

PICO Confirmation


Assessment Report


Public Summary Document


Meetings for this Application


10-11 December 2020